Fibroblast growth factor receptors and methods for their use
AssigneeGenesis Research & Development Corporation Limited
InventorsLorna Strachan, Matthew Sleeman, Nevin Abernethy, Rene Onrust, Krishanand Kumble, James Greg Murison
Life of this patent
Estimating the term…
Abstract
Isolated fibroblast growth factor receptor polypeptides and polynucleotides encoding such polypeptides are provided, together with expression vectors and host cells comprising such isolated polynucleotides. Methods for the use of such polypeptides and polynucleotides are also provided.
Claims28
An isolated polypeptide comprising a sequence selected from the group consisting of:
- SEQ ID NO:
- 5-8 and 13-15.
An isolated polypeptide comprising a sequence selected from the group consisting of:
- (a) sequences having at least 75% identity to a sequence provided in SEQ ID NO:
- 5-8 and 13-15;
- (b) sequences having at least 90% identity to a sequence provided in SEQ ID NO:
- 5-8 and 13-15;
- and
- (c) sequences having at least 95% identity to a sequence provided in SEQ ID NO:
- 5-8 and 13-15,
- wherein the polypeptide possesses at least one functional property that is substantially the same as a functional property of a sequence of SEQ ID NO:
- 5-8 and 13-15.
An isolated polynucleotide comprising a sequence selected from the group consisting of:
- (a) complements of a sequence provided in SEQ ID NO:
- 1-4 and 9;
- (b) reverse complements of a sequence provided in SEQ ID NO:
- 1-4 and 9;
- (c) reverse sequences of a sequence provided in SEQ ID NO:
- 1-4 and 9;
- (d) sequences having at least 75% identity to a sequence provided in SEQ ID NO:
- 1-4 and 9;
- and
- (e) sequences having at least 90% identity to a sequence provided in SEQ ID NO:
- 1-4 and 9;
- and
- (f) sequences having at least 95% identity to a sequence of SEQ ID NO:
- 1-4 and 9.
An isolated polypeptide comprising at least a functional portion of an amino acid sequence selected from the group consisting of sequences provided in SEQ ID NO:
- 5-8 and 13-15.
A method for inhibiting the expression of osteopontin in a population of cells, comprising reducing the amount of a polypeptide in the cells, the polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) a sequence provided in SEQ ID NO:
- 5-8 and 13-15;
- (b) sequences having at least 75% identity to a sequence provided in SEQ ID NO:
- 5-8 and 13-15
- (c) sequences having at least 90% identity to a sequence provided in SEQ ID NO:
- 5-8 and 13-15;
- and
- (d) sequences having at least 95% identity to a sequence provided in SEQ ID NO:
- 5-8 and 13-15.
A method for inhibiting the expression of osteopontin in a population of cells, comprising inhibiting the activity of a polypeptide in the cells, the polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) a sequence provided in SEQ ID NO:
- 5-8 and 13-15;
- (b) sequences having at least 75% identity to a sequence provided in SEQ ID NO:
- 5-8 and 13-15;
- (c) sequences having at least 90% identity to a sequence provided in SEQ ID NO:
- 5-8 and 13-15;
- and
- (d) sequences having at least 95% identity to a sequence provided in SEQ ID NO:
- 5-8 and 13-15.
A method for treating a disorder characterized by an elevated level of osteopontin, comprising administering an antibody, or an antigen-binding fragment thereof that binds specifically to a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) sequences provided in SEQ ID NO:
- 5-8 and 13-15;
- (b) sequences having at least 75% identity to a sequence provided in SEQ ID NO:
- 5-8 and 13-15;
- (c) sequences having at least 90% identity to a sequence provided in SEQ ID NO:
- 5-8 and 13-15;
- and
- (d) sequences having at least 95% identity to a sequence provided in SEQ ID NO:
- 5-8 and 13-15.
A method for treating a disorder characterized by an elevated level of osteopontin, comprising administering an anti-sense oligonucleotide that binds specifically to a polynucleotide comprising a sequence selected from the group consisting of:
- (a) sequences provided in SEQ ID NO:
- 1-4 and 9;
- (b) sequences having at least 75% identity to a sequence provided in SEQ ID NO:
- 1-4 and 9;
- (c) sequences having at least 90% identity to a sequence provided in SEQ ID NO:
- 1-4 and 9;
- and
- (d) sequences having at least 95% identity to a sequence provided in SEQ ID NO:
- 1-4 and 9.
A method for treating a disorder characterized by an elevated level of osteopontin, comprising administering a small interfering RNA molecule that corresponds to a polynucleotide comprising a sequence selected from the group consisting of:
- (a) sequences provided in SEQ ID NO:
- 1-4 and 9;
- (b) sequences having at least 75% identity to a sequence provided in SEQ ID NO:
- 1-4 and 9;
- (c) sequences having at least 90% identity to a sequence provided in SEQ ID NO:
- 1-4 and 9;
- and
- (d) sequences having at least 95% identity to a sequence provided in SEQ ID NO:
- 1-4 and 9.
Dependencies are inferred from the claim text.